title: In vitro kinetics of delivery of tobramycin and ofloxacin from osmotic hydro gel expanders.
abstract: OBJECTIVE
  High-hydrophilic osmotic self-inflating hydro gel expanders are well-accepted for implantation to achieve tissue expansion in defined parts of the body like skin, breast and orbital soft tissue. To prevent post-implantation infections effective antibiotic prophylaxis might be helpful. The suitability of this hydro gel consisting of a co-polymer of N-vinyl-pyrolidone and methyl-methacrylate as a drug delivery system for antibiotics was investigated in a laboratory setting simulating the orbit in a newborn.
  
  
  METHODS
  In a first setting the dry expanders were incubated in a 0.3% solution (5 ml) of tobramycin and ofloxacin for 24 h (n = 10 for each substance, adsorbing 2.4 ml of the 0.3% solution, i.e. 7,200 μg antibiotic). Addressing the release of both antibiotics, the concentrations in 15 ml elution medium (0.9% sodium chloride, renewed after every sampling) were measured after 0.25, 1, 2, 6, 24, 48 and 72 h of elution. To simulate the clinical use in a second setting the expanders were dried after incubation in a 0.3% and 0.03% solution of tobramycin (n = 5 for each concentration) before measuring the release.
  
  
  RESULTS
  The cumulative amount of tobramycin released after 72 h reached 7,157 μg, i.e. 99% of the initially loaded antibiotic. The cumulatively released amount of ofloxacin was 5,505 μg (76% of loading dose). Main fraction of release (about two thirds) was detected for both antibiotics for a elution period 0 - 24 h. In the periods 24 - 48 and 48 - 72 h the released amount of tobramycin was significantly higher than for ofloxacin. The release from expander dried after loading tobramycin was comparable: The cumulatively released amount of 0.3% and 0.03% incubation solution was 99% and 79% of loading dose, respectively.
  
  
  CONCLUSIONS
  The investigated hydro gel expanders soaked in antibiotic solution can store and further on release sufficient amounts of tobramycin or ofloxacin to produce antimicrobial effective concentrations in vitro in the surrounding environment according to the breakpoints reported by EUCAST [14]. This principle, when used in a clinical setting, might help to eliminate post-implantation infection, which is one of the major complications in clinical use.
authors: Institute of Clinical Pharmacology, University of Rostock, Germany. rainer-wacke@med.uni-rostock.de
authors: R
authors: R
authors: Wacke
authors: B
authors: B
authors: Drewelow
authors: R G
authors: RG
authors: Mundkowski
authors: R F
authors: RF
authors: Guthoff
authors: M P
authors: MP
authors: Schittkowski
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D016231:Fluorescence Polarization Immunoassay; D020100:Hydrogels; D007700:Kinetics; D020366:Methylmethacrylate; D015242:Ofloxacin / Q000008:administration & dosage*; D009995:Osmosis; D011205:Povidone; D012995:Solubility; D012996:Solutions; D014031:Tobramycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D020100:Hydrogels; D012996:Solutions; D020366:Methylmethacrylate; D015242:Ofloxacin; D011205:Povidone; D014031:Tobramycin